Aduro and Merck to Start Clinical Trial Assessing Immunotherapy Combo in Gastric Cancer – Immuno-Oncology News
Community Financial News |
Aduro and Merck to Start Clinical Trial Assessing Immunotherapy Combo in Gastric Cancer
Immuno-Oncology News Aduro Biotech is collaborating with Merck to study the combination of Aduro's Listeria-based immunotherapy CRS-207 with Merck's anti-PD-1 Keytruda (pembrolizumab) in gastric cancer patients. The multicenter Phase 1 clinical trial, which will enroll … Aduro Biotech Announces Clinical Collaboration With Merck To Evaluate The Combination Of Aduro's CRS-207 With … |
